Jump to content

Rimegepant: Difference between revisions

From Pharmacopedia
[unchecked revision][checked revision]
← Older edit

MDElliottMD (talk | contribs)

3 user groups
5,187 edits
VisualWikitext
Assign pharmacological categories from List_of_CNS-active_medicines
parser-claude: Rimegepant MedTemplate refill, Top 300 stub upgrade
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
{{MedTemplate
{{MedTemplate
| generic           = Rimegepant
| generic           = Rimegepant
| brand             = Nurtec
| brand             = Nurtec ODT
| structure         =  
| structure         =
| classes           = Gepant, Migraine medicine
| classes           = [[:Category:Gepants|Gepant (small-molecule CGRP receptor antagonist)]], [[:Category:Antimigraine medicines|Antimigraine medicine]], [[:Category:Analgesics|Analgesic]]
| mechanism          = CGRP receptor antagonist
| uses             = <vote slug="acute-migraine-use">Acute migraine with or without aura (FDA, 2020)</vote>, <vote slug="migraine-prophylaxis-use">Migraine preventive treatment (FDA, 2021; '''the first medicine with both acute and preventive migraine indications''')</vote>
| uses               =  
| starting_dose     = Acute migraine: 75 mg PO at onset, maximum one dose per 24 hours. Preventive: 75 mg PO every other day
| starting_dose     =  
| preparations     = Orally disintegrating tablet 75 mg
| preparations       =  
| fda_max           = 75 mg per dose; one dose per 24 hours (acute); one dose every other day (preventive)
| fda_max          =  
| pill_id           =
| routes             =  
| routes           = Oral (sublingual disintegration)
| onset             =  
| onset             = 1-2 hours for migraine relief
| duration           =  
| duration         = ~48 hours of headache freedom
| halflife           =
| halflife          = ~11 hours<ref name="nurtec-label">FDA Prescribing Information, Nurtec ODT (rimegepant), Biohaven/Pfizer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212728s003lbl.pdf</ref>
| bioavailability    =
| bioavailability   = ~64% (oral)<ref name="nurtec-label" />
| pregnancy         =  
| pregnancy        = Limited human data.{{citation needed}}
| legal              =  
| legal             = [[USLegal:Prescription only|Rx-only]] in US
| intro              =
| mechanism        = <vote slug="rimegepant-mech-claim">Small-molecule antagonist of the calcitonin gene-related peptide (CGRP) receptor, the first oral CGRP-targeting agent in widespread clinical use. CGRP is the dominant pro-migraine neuropeptide released from trigeminal nerve terminals; blocking its receptor blunts the neurogenic inflammation that drives migraine pain.</vote> '''Unlike triptans, rimegepant does not cause vasoconstriction''' and is safe in patients with coronary artery disease and other vascular conditions where triptans are contraindicated. The dual acute-and-preventive indication is the unique pharmacological feature among migraine medicines. The second-generation gepants (rimegepant, ubrogepant, atogepant) have a clean hepatic-safety profile compared to the first-generation gepants withdrawn during development for hepatotoxicity<ref name="nurtec-label" />.
| pharmacokinetics   =  
| pharmacodynamics  =  
| indications        =  
| dosing             =  
| effects            =
| interactions      = <pharmaInteractions/>
| pregnancy_details  =
| monitoring        =
| counseling        =
| anecdotes          =
| seealso            =
| references        =  
}}
}}


== References ==
<references />


[[Category:Migraine Medicines]]
[[Category:Gepants]]
[[Category:Gepants (CGRP Receptor Antagonists)]]
[[Category:Antimigraine medicines]]
[[Category:Analgesics]]
[[Category:Analgesics]]

Latest revision as of 07:21, 23 May 2026

Gepant (small-molecule CGRP receptor antagonist), Antimigraine medicine, Analgesic
Rimegepant
Nurtec ODT

Experience

👥 No personal reports yet
⚕ No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
Gepant (small-molecule CGRP receptor antagonist), Antimigraine medicine, Analgesic
Common uses
Acute migraine with or without aura (FDA, 2020)0, Migraine preventive treatment (FDA, 2021; the first medicine with both acute and preventive migraine indications)0
Pharmacy
Starting dose
Acute migraine: 75 mg PO at onset, maximum one dose per 24 hours. Preventive: 75 mg PO every other day
Preparations
Orally disintegrating tablet 75 mg
US FDA Max
75 mg per dose; one dose per 24 hours (acute); one dose every other day (preventive)
Pharmacology
Routes
Oral (sublingual disintegration)
Onset
1-2 hours for migraine relief
Duration
~48 hours of headache freedom
Half-life
~11 hours[1]
Bioavailability
~64% (oral)[1]
Pregnancy
Limited human data.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Small-molecule antagonist of the calcitonin gene-related peptide (CGRP) receptor, the first oral CGRP-targeting agent in widespread clinical use. CGRP is the dominant pro-migraine neuropeptide released from trigeminal nerve terminals; blocking its receptor blunts the neurogenic inflammation that drives migraine pain.0 Unlike triptans, rimegepant does not cause vasoconstriction and is safe in patients with coronary artery disease and other vascular conditions where triptans are contraindicated. The dual acute-and-preventive indication is the unique pharmacological feature among migraine medicines. The second-generation gepants (rimegepant, ubrogepant, atogepant) have a clean hepatic-safety profile compared to the first-generation gepants withdrawn during development for hepatotoxicity[1].

References

  1. ↑ 1.0 1.1 1.2 FDA Prescribing Information, Nurtec ODT (rimegepant), Biohaven/Pfizer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212728s003lbl.pdf
Retrieved from "https://pharmacopedia.wiki/index.php?title=Rimegepant&oldid=6712"